Physician profile
Barry Gruber
NPI 1710912431
$742,177.27
in general payments reported to CMS, 2019-2025
55 companies · $112K in 2025
The $112K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245K · 2020: $80K · 2021: $77K · 2022: $71K · 2023: $83K · 2024: $73K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Food and Beverage: $22K · Consulting Fee: $21K · Honoraria: $20K · Travel and Lodging: $17K · Education: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $187,812.50 |
| Food and Beverage | $21,889.43 |
| Consulting Fee | $21,401.00 |
| Honoraria | $20,137.50 |
| Travel and Lodging | $16,683.31 |
| Education | $359.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411,347.39 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Horizon Therapeutics Plc | $56,028.94 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42,139.25 | 2019-2025 | Ofev, Cyltezo |
| Radius Health, INC. | $41,703.91 | 2019-2025 | Tymlos |
| Pacira Therapeutics, INC. | $31,992.53 | 2019-2021 | |
| Abbvie INC. | $29,020.84 | 2019-2025 | |
| United Rheumatology | $28,798.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26,500.72 | 2019-2024 | Orencia |
| Regeneron Healthcare Solutions, INC. | $14,773.71 | 2019 | |
| Mallinckrodt Enterprises LLC | $10,482.90 | 2019 | |
| Celgene Corporation | $10,374.07 | 2019 | |
| Kyowa Kirin, INC. | $7,865.03 | 2024-2025 | Crysvita |
| Genzyme Corporation | $6,501.52 | 2020-2025 | |
| Janssen Biotech, INC. | $4,849.66 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $4,344.49 | 2019-2025 | Tremfya |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $2,876.99 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,934.17 | 2020-2025 | Acthar |
| Fresenius Kabi USA, LLC | $1,637.65 | 2022-2023 | Idacio |
| Ucb, INC. | $1,636.92 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,131.95 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $834.93 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $697.91 | 2019-2024 | Taltz, Omvoh, Zepbound |
| Novartis Pharmaceuticals Corporation | $562.97 | 2019-2025 | |
| Genentech USA, INC. | $538.01 | 2019-2025 | Actemra, Rituxan |
| Ani Pharmaceuticals, INC. | $518.68 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $411.79 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $331.73 | 2021-2025 | Saphnelo |
| Biohaven Pharmaceutical Holding Company LTD. | $318.81 | 2022 | |
| Organon LLC | $284.95 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Alexion Pharmaceuticals, INC. | $151.58 | 2022-2025 | Strensiq |
| Medexus Pharma, INC. | $145.90 | 2019 | |
| Ferring Pharmaceuticals INC. | $138.88 | 2019-2024 | Euflexxa |
| Merck Sharp & Dohme LLC | $130.68 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $129.81 | 2025 | |
| Janssen Pharmaceuticals, INC | $126.10 | 2025 | Tremfya |
| Actelion Pharmaceuticals US, INC. | $116.90 | 2021-2024 | Uptravi, Opsumit |
| Zimmer Biomet Holdings, INC. | $84.65 | 2023-2024 | Visco-3 Sodium Hyaluronate, Accufill |
| Kiniksa Pharmaceuticals International, Plc | $77.36 | 2024 | Arcalyst |
| Almatica Pharma LLC | $67.37 | 2025 | Teriparatide |
| Hikma Pharmaceuticals USA | $64.89 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $61.32 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $54.62 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $49.37 | 2023-2025 | Zilretta, Iovera |
| Depuy Synthes Sales INC. | $47.03 | 2023-2024 | Orthovisc, Monovisc |
| Antares Pharma, INC. | $46.20 | 2019-2020 | |
| Sandoz INC. | $39.11 | 2023-2025 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $30.15 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $29.08 | 2023 | Arcalyst |
| Bioxcel Therapeutics, INC. | $28.26 | 2023 | Igalmi |
| Bioventus LLC | $25.56 | 2019 | |
| Alvogen INC | $24.82 | 2025 | Teriparatide |
| Teva Pharmaceuticals USA, INC. | $19.60 | 2024 | Truxima |
| Scilex Pharmaceuticals INC. | $18.60 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.79 | 2023 | Seglentis |
| Shire North American Group INC | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Gruber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.